CX 2023 heralds new era of yearround education for the vascular community

DELEGATES CAN EXPECT another full programme of sessions and additional events on the third and final day of the 45th CX meeting. Stay tuned for the announcement of the winner of the Hurting Leg competition—a new feature of the 2023 programme—as well as a full-day venous and Hurting Leg workshop, audience polling in this morning’s thoracic session, and a Podium First in the CX Innovation Showcase later today. As the meeting draws to a close, the time has also come to look ahead at what is in store for 2024.

Following this landmark anniversary symposium, headlined by the first-time BASIL-2 presentation on Tuesday, the CX Symposium is set to return in 2024 with a controversies update. Next year, the meeting will take place in a new venue, the international ExCeL centre, with the aim of offering more space for the plenary programme, as well as larger exhibition and workshop spaces.

The in-person and virtual CX 2023 event might be drawing to a close, but the education does not end here. All presentations, as well as CX materials from previous years, will be available to members of the online community at CXVascular.com after the event. Stay up to date with the latest updates in the vascular and endovascular world year-round with this new interactive platform, ahead of next year’s CX 2024 in-person and virtual event.

CX Podium First: Statins save lives after aortic repair regardless of dose

Statin treatment after aortic repair is associated with improved long-term survival, while dose does not matter. This was the key message from a Podium First presentation delivered by Kevin Mani (Uppsala, Sweden) during yesterday’s abdominal aortic session in Kensington 1. The CX audience showed their support for this conclusion, with 89% agreeing with the statement ‘Statins save lives’ during discussion time.

Continued on page 4

Mani began by underlining the fact that abdominal aortic aneurysm (AAA) is a cardiovascular disease that shares risk factors with atherosclerotic cardiovascular disease (ASCVD). According to the American Heart Association (AHA), the presenter detailed, AAA is in fact classified as one of the ASCVDs.

“AAA patients have a higher mortality than the general

Continued on page 2 population due to cardiovascular disease,” Mani noted, adding that statin treatment is associated with improved survival in patients with ASCVD.

The presenter detailed that current European Society for Vascular Surgery (ESVS) guidelines on the management of abdominal aortoiliac artery aneurysms, published in 2019, suggest that patients with AAA should have blood pressure control, statins and antiplatelet therapy.

“This is a class IIa recommendation with level B evidence,” the presenter specified, which he said indicates that “probably all patients” with AAA should have statin treatment.

The AHA guidelines, Mani highlighted, split statin treatment into high dose and moderate to low dose. “The suggestion is that patients with ASCVD including those with AAA should have high-dose statin treatment,” the presenter shared with the Kensington 1 audience. “However,” he said, “the evidence for what dose should be given to AAA patients is non-existent, and the vascular surgical guidelines do not recommend a specific dose for AAA patients.”

To address this gap in the literature, Mani

Continued from page 1 and colleagues conducted a national study assessing the potential benefit of statin treatment in AAA patients and assessed whether dose has an effect. The team used four national registries and then cross-matched these to identify all AAA repairs performed in Sweden between the years of 2006 and 2018, the presenter explained. The team then assessed statin treatment by combining patient data and the national prescribed drug registry, looking at outcomes in terms of death, cause of death and rehospitalisation, also using national registries.

Mani detailed that the researchers performed three analyses, the first looking at 90-day mortality for patients who had statin treatment preoperatively, the second assessing statin versus no statin treatment postoperatively, and the final one examining high-dose versus low-to-moderate-dose statin treatment postoperatively, considering overall survival, aortic-related survival and freedom from cardiovascular events. Propensity score matching was used to ensure that the groups were comparable in terms of baseline comorbidities and characteristics.

The presenter revealed that approximately 60% of the 11,000 patients who underwent AAA repair in the national study had statin treatment prior to undergoing repair. Postoperatively, he added, half of the patients had continuous statin treatment 80% of the time after the operation. In both instances, the rates were higher among men compared to women.

Looking at perioperative mortality, Mani reported that this was the same in the group on statin treatment versus no statin treatment and was equal for the endovascular aneurysms repair (EVAR) and open repair cohorts, with an overall 90-day mortality of just under 3%.

The presenter also shared the finding that patients on

Acute Stroke Consensus

statin treatment had an improved survival in the long term, and that overall survival was “significantly improved” in a propensity score-matched group of patients with or without continuous statin treatment after AAA repair. Aortic-related survival was improved with statin treatment, he stated, as was freedom from cardiovascular events, if the patients were on statin treatment.

Finally, the team assessed the high-dose statin group versus the low-to-moderate-dose group. “There was no effect of the dose of statins, neither on overall survival nor on aortic-related survival or cardiovascular events,” he communicated. “These were equal, irrespective of dose.”

“In conclusion,” the presenter summarised, “statin treatment is beneficial in AAA patients with improved longterm survival, as well as improved freedom from aorticrelated complications and cardiovascular events.” However, he added the caveat that there is no support in the study for high-intensity statin treatment after AAA repair, and that perioperative mortality was not affected by statin treatment.

In a subsequent discussion, panellist Janet Powell (London, United Kingdom) asked whether the study results are independent of low-density lipoprotein (LDL) cholesterol levels. Mani responded that the team does not have such data. However, he highlighted the fact that the AHA recommendation for high-dose statins for patients with AAA below the age of 75 is irrespective of their LDL levels. “Clearly, this is an area where we need to work more on how we achieve the adequate effect of statins by looking at LDL levels,” he remarked, considering future research in this space.